Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04331275 · ClinicalTrials.gov registry record · Phase 2
Viral Specific T-cells for Treatment of Viral Infections After Solid Organ Transplant
A Phase 2 study of Viral Infection and Solid Organ Transplant, sponsored by Children's Hospital Medical Center, Cincinnati.
- Active
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 1
- Study location
NCT04331275: Active Phase 2 study of Viral Infection and Solid Organ Transplant, sponsored by Children's Hospital Medical Center, Cincinnati.
NCT04331275 is a Phase 2 study of Viral Infection and Solid Organ Transplant that is active but no longer recruiting, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 42 participants, below the 225-participant average among 11 other Viral Infection trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04331275, a Phase 2 study of Viral Infection and Solid Organ Transplant, is active but no longer recruiting, sponsored by Children's Hospital Medical Center, Cincinnati.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to learn more about the use of viral specific T-lymphocytes (VSTs) to treat viral infections that may happen after solid organ transplant (SOT). VSTs are cells specially designed to fight viral infections that may happen after a solid organ transplant. These cells are created from a blood sample collected from the study participant. Solid organ transplant and the use of immunosuppressive medications reduces the body's ability to fight infections. Viral infections are a common problem after transplant and can cause significant complications. Reduction of immunosuppression may put the organ at risk of rejection. Moreover, treatment of viral infections is expensive and time consuming, with families often administering prolonged treatments with intravenous anti-viral medications, or patients requiring prolonged admissions to the hospital. The medicines can also have side effects like damage to the kidneys or reduction in the blood counts, so in this study the investigators are trying to find a better way to treat these infections and minimize complications.
Primary Outcome
Of the patients who had a VST culture initiated, successful production of VST cells is defined as meeting the protocol-defined release criteria.
Conditions Studied
Interventions
- BIOLOGICAL Viral Specific T-cells (VSTs)
Study Locations (1)
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2020-08-18 |
| Est. Completion | 2028-09 |
| Phase | Phase 2 |
What the registry record for NCT04331275 still lists
NCT04331275 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 225-participant average among 11 other Viral Infection trials with a reported enrollment target (81% lower).
The record links to 2 conditions, with Viral Infection appearing as the primary indexed condition, and to 1 intervention - of which Viral Specific T-cells (VSTs) is the first listed.
NCT04331275 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT04331275 about?
NCT04331275 is a clinical study titled "Viral Specific T-cells for Treatment of Viral Infections After Solid Organ Transplant". The purpose of this research study is to learn more about the use of viral specific T-lymphocytes (VSTs) to treat viral infections that may happen after solid organ transplant (SOT). VSTs are cells specially designed to fight viral infections that may happen after a solid organ transplant. These cel...
What is the current status of trial NCT04331275?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2020-08-18. Estimated completion is 2028-09.
What conditions does trial NCT04331275 study?
This clinical trial studies the following conditions: Viral Infection, Solid Organ Transplant.
What interventions are being tested in trial NCT04331275?
The interventions under investigation include: Viral Specific T-cells (VSTs) (BIOLOGICAL).
Who is sponsoring clinical trial NCT04331275?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04331275 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Viral Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04331275's enrollment target sits among peer trials
42 9th of 11 higher than 3 of 11 other Viral Infection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Viral Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Third Party Viral Specific T-cells (VSTs)
RECRUITING · Phase 2
-
Trial of Scheduled Versus Treatment Administration of Donor-Derived Viral Specific T-cells for Viral Infections After Stem Cell Transplant
RECRUITING · Phase 2
-
Smell Changes & Efficacy of Nasal Theophylline
COMPLETED · Phase 2
-
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
RECRUITING · Phase 1
-
Adoptive Cord Blood Immunotherapy for EBV, CMV, BKV and Adenovirus Reactivation/Infection or Prophylaxis
RECRUITING · Phase 1
-
School Inner City Air Study
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI